Utility of dopamine transporter imaging (123-I Ioflupane SPECT) in the assessment of movement disorders;Utilidad de la imagen de transportadores de dopamina (SPECT cerebral con Ioflupano I-123) en la valoración de los trastornos del movimiento

Revista Espanola de Medicina Nuclear

Volumn 23, Issue 4, 2004, Pages 245-252

  Garcia Vicente A M ^a   Vaamonde Cano, J ^a   Poblete Garcia V M ^a   Rodado Marina, S ^a   Cortes Romera M ^a   Ruiz Solis S ^a   Ibanez Alonso R ^a   Soriano Castrejon A ^a  

^a Hospital Alarcos   (Spain)

Author keywords

123 I Ioflupane; Dopamine transporters; Parkinsonism

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; IOFLUPANE I 123; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ESSENTIAL TREMOR; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MOTOR DYSFUNCTION; PARKINSONISM; PRESYNAPTIC NERVE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

EID: 4344658034     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13063066     Document Type: Article

References (36)

1. Álvarez González L, Sánchez Catasus C, Álvarez Gónzalez E. SPECT en la enfermedad de Parkinson y otros trastornos del movimiento. Rev Mex Neurociencia 2001;2:169-75.
2. Salemi G, Savettieri G, Rocca WA, Meneghini F, Saporito V, Morgante L, et al. Prevalence of essential tremor: a door-to-door survey in Terrasini Sicily. Sicilian Neuro-Epidemiologic Study Group Neurology 1994;44:61-4.
3. Martí-Masso JF, Poza JJ. Drug-induced or aggravated Parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 1996;11:10-5.
4. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism- a prospective study. Can J Neurol Sci 1991;18:275-8.
5. Hughes AJ, Daniel SE, Kilford L, Less AJ. Accuracy of clinical diagnosis of idiopatic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
6. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001;22:819-27.
7. Marek K, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. 123 I beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinson's disease. Neurology 1996;46:231-7.
8. Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, et al. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by iodine-123-I beta-CIT SPECT. J Neurol 1998;245:14-20.
9. Seibyl J, Marek K, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased SPECT 123 I beta-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 1995;38:589-98.
10. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natk Acad Scl 1993;90:11965-9.
11. Rinne JO, Kiokka JT, Bergstrom KA, Rinne UK. Striatal dopamine transporters in different disability stages of Parkinson's disease studied with 123-I beta-CIT SPECT. Parkinsonism Relat Disord. 1995;22:47-51.
12. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. 123 I-beta- CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-94.
13. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-7.
14. Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P, Wenger S, et al. Imaging of dopamine transporters with iodine-123 B-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
15. Messa C, Volonté MA, Fazio F, Zito F, Carpinelli A, d'Amico A, et al. Differential distribution of striatal 123 I beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998;25:1270-6.
16. Booij J, Speelman JD, Horstink M, Wolters E. The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from other forms of parkinsonism. Eur J Nucl Med 2001;28:266-72.
17. Naumann M, Pirker W, Reiners K, Langer K, Becker G, Brüke T. 123 I beta-CIT SPECT in DOPA-responsive dystonia. Mov Disord 1997;12:448-51.
18. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by 123 I beta-CIT SPECT is normal in DOPA-responsive dystonia. Ann Neurol 1998;43:792-800.
19. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82.
20. Pahwa R, Koller W. Is there a relationship between Parkinson's disease and essential tremor? Clin Neuropharmacol 1993;16:30-5.
21. Lou J, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology 1991;41:324-38.
22. Gwinn-Hardy K, Adler C, Caviness J. The Michigan kindred: a large family with Parkinson's disease. Mov Disord 1998;13:60.
23. Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998;155:768-73.
24. Martí-Massó JF, Ruis Martínez J. Parkinsonismos secundarios. En: Jiménez-Jimenez FJ, Luquin MR, Molina JA, eds. Tratado de los trastornos del movimiento. Madrid. 1998; p. 513-42.
25. Muñoz E, Aguilar M, López del Val J. Otras causas de parkinsonismo. En: Jiménez-Jimenez FJ, Luquin MR, Molina JA, eds. Tratado de los trastornos del movimiento. Madrid. 1998; p. 543-64.
26. Van Gerpen JA. Drug-induced parkinsonism. Neurolog 2002;8:363-70.
27. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994;8:293-306.
28. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980;10:55-72.
29. Gershanik OS. Drug-induced movement disorders. Curr Opin Neurol Neurosurg 1993;6:369-76.
30. Innis R, Marek K, Sheff, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with carbidopa/levodopa or selegiline on striatal transporter imaging with iodine-123- beta-CIT. Mov Disord 1999;14:436-43.
31. Ahlskog J, Ryan J, O'Connor M, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-50.
32. Peters S, Eising EG, Przuntek H, Müller T. Vascular parkinsonism: a case report and review of the literature. J Clin Neuroscience 2001;8:268-71.
33. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism- a clinicopathologic study. Stroke 1997;28:965-9.
34. Van Zagten M, Lodder J, Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 1998;13:89-95.
35. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989;4:249-60.
36. Katzenschlager R, Costa D, Garschlager W, O'Sullivan J, Zijlmans J, Gacinovic S, et al. Iodine-123 FP-CIT SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol 2003;53:489-96.